Scholarlink

Background <p>Trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) increasingly used in HER2-negative breast cancer. We hypothesized that treatment benefit would vary across HER2-null, HER2-ultra-low, and HER2-low subgroups of HER2-negative breast cancer patients. We also aimed to study the clinical impact of different sequencing of the two ADCs.</p> Methods <p>We analyzed a large, real-world cohort of 4,030 HER2-negative breast cancer specimens from patients treated with T-DXd or SG. Tumors underwent molecular profiling including HER2 status (IHC, CISH) and hormone receptor (HR) status (IHC) at Caris Life Sciences (Phoenix, AZ, USA). Real-world clinical data were obtained from insurance claims and analyzed by Cox proportional hazards.</p> Results <p>HER2-low, HER2-ultra-low, and HER2-null cohorts treated with T-DXd had decreasing time-on-treatment (TOT; 4.8, 4.1, and 3.5 mo., respectively, <i>P</i> &lt; 0.001), while HER2 status had little impact on SG TOT (3.0, 2.8, and 3.4 mo., respectively). Patients with HR+/HER2-negative tumors showed longer TOT when treated with T-DXd only (<i>n</i> = 1,049) than with SG-only (<i>n</i> = 453), even in the HER2-null subset (<i>P</i> &lt; 0.001). In all HER2-negative patients treated with both ADCs, T-DXd-first (<i>n</i> = 547) or SG-first (<i>n</i> = 432) showed no cumulative TOT difference (10.4 vs. 10.8 mo., <i>P</i> = 0.356); however, the HER2-null subset showed preference for SG-first and this was restricted to the HR- subset [TOT: 11.7 vs. 7.4 mo., hazard ratio = 0.478 (95% CI: 0.333–0.685), <i>P</i> &lt; 0.0001; OS: 19.7 vs. 11.8 mo., hazard ratio = 0.478 (95% CI: 0.303–0.756)].</p> Conclusions <p>Analysis of this large real-world dataset allowed interrogation of T-DXd and SG benefit and treatment sequencing across HER2-negative subsets, providing important clinical insights into two widely used ADCs in breast cancer. We demonstrate improved relative outcomes associated with T-DXd in HR+ tumors across all HER2-negative subgroups and comparable benefit of the two ADCs in TNBC. Sequencing preference was seen in HR−/HER2-null patients only, favoring SG-first for TOT and OS. These findings warrant further validation in independent cohorts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月11日

查看全文
  • George W. Jr. Sledge,
  • Joanne Xiu,
  • Jeffrey Peter Solzak,
  • Jennifer Ribeiro,
  • Reshma L. Mahtani,
  • Maryam B. Lustberg,
  • Matthew J. Oberley,
  • Milan Radovich,
  • David Spetzler

摘要

Background

Trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) increasingly used in HER2-negative breast cancer. We hypothesized that treatment benefit would vary across HER2-null, HER2-ultra-low, and HER2-low subgroups of HER2-negative breast cancer patients. We also aimed to study the clinical impact of different sequencing of the two ADCs.

Methods

We analyzed a large, real-world cohort of 4,030 HER2-negative breast cancer specimens from patients treated with T-DXd or SG. Tumors underwent molecular profiling including HER2 status (IHC, CISH) and hormone receptor (HR) status (IHC) at Caris Life Sciences (Phoenix, AZ, USA). Real-world clinical data were obtained from insurance claims and analyzed by Cox proportional hazards.

Results

HER2-low, HER2-ultra-low, and HER2-null cohorts treated with T-DXd had decreasing time-on-treatment (TOT; 4.8, 4.1, and 3.5 mo., respectively, P < 0.001), while HER2 status had little impact on SG TOT (3.0, 2.8, and 3.4 mo., respectively). Patients with HR+/HER2-negative tumors showed longer TOT when treated with T-DXd only (n = 1,049) than with SG-only (n = 453), even in the HER2-null subset (P < 0.001). In all HER2-negative patients treated with both ADCs, T-DXd-first (n = 547) or SG-first (n = 432) showed no cumulative TOT difference (10.4 vs. 10.8 mo., P = 0.356); however, the HER2-null subset showed preference for SG-first and this was restricted to the HR- subset [TOT: 11.7 vs. 7.4 mo., hazard ratio = 0.478 (95% CI: 0.333–0.685), P < 0.0001; OS: 19.7 vs. 11.8 mo., hazard ratio = 0.478 (95% CI: 0.303–0.756)].

Conclusions

Analysis of this large real-world dataset allowed interrogation of T-DXd and SG benefit and treatment sequencing across HER2-negative subsets, providing important clinical insights into two widely used ADCs in breast cancer. We demonstrate improved relative outcomes associated with T-DXd in HR+ tumors across all HER2-negative subgroups and comparable benefit of the two ADCs in TNBC. Sequencing preference was seen in HR−/HER2-null patients only, favoring SG-first for TOT and OS. These findings warrant further validation in independent cohorts.